Consequences of Brexit on biosimilars

Journal of Bioanalysis & Biomedicine

ISSN: 1948-593X

Open Access

Consequences of Brexit on biosimilars

7th European Biosimilars Congress

May 15-16, 2017 Munich, Germany

Christian B Fulda

Jones Day, Germany

Posters & Accepted Abstracts: J Bioanal Biomed

Abstract :

The European Union introduced the first regulatory pathway to biosimilars more than a decade ago, making a centralized authorization valid throughout the European Union available for biosimilars. The validity of these authorizations in the UK post Brexit is called into question. What is more, marketing authorization holders have to reside in the European Union and close to 40% of all central marketing authorizations (not only biosimilars) are held by companies residing in the UK. Thus, access to the UK market is thrown into question, and existing corporate structures for marketing authorization holders have to be revisited. Also distribution contracts may have to be renegotiated, where it comes to the territory of the UK. Adding uncertainty for the industry is the expected move by the European Medicines Agency from London.

Biography :

Email: [email protected]

Google scholar citation report
Citations: 1993

Journal of Bioanalysis & Biomedicine received 1993 citations as per google scholar report

Journal of Bioanalysis & Biomedicine peer review process verified at publons

Indexed In

arrow_upward arrow_upward